Know Cancer

or
forgot password

Investigation of Lactate Measured Using Magnetic Resonance Spectroscopy as a Biomarker of Tumour Response


N/A
18 Years
80 Years
Not Enrolling
Both
Cancer

Thank you

Trial Information

Investigation of Lactate Measured Using Magnetic Resonance Spectroscopy as a Biomarker of Tumour Response


Inclusion Criteria:



Cohort 1:lymphoma patients

- minimum lesion size of 2cm

- not pre-treated but scheduled to be treated with CHOP (Cyclophosphamide,
Hydroxydaunomycin,Oncovin and Prednisilone)

Cohort 2:Colorectal patients

- metastatic disease of at least 2cm

- not pre-treated

Cohort 3:Phase 1 Drug Development

- minimum lesion size at least 2cm

Exclusion Criteria:

- MRI incompatible metal implants

- Claustrophobia

- Inability to tolerate a 40 minute MRI scan

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Correlation between changes in MRS lactate measurements at two time points after treatment and clinical response

Outcome Time Frame:

7 and 21 days post treatment

Safety Issue:

No

Principal Investigator

Nandita deSouza, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

ICR

Authority:

United Kingdom: Research Ethics Committee

Study ID:

13/LO/0536 CCR3939

NCT ID:

NCT01881386

Start Date:

July 2013

Completion Date:

Related Keywords:

  • Cancer
  • Magnetic Resonance Spectroscopy
  • Lactate

Name

Location